arrow
P

Patrik Andersson

AstraZeneca
H指数:34
被引数:3,827

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based Therapeutics

从行业视角探讨ICH S13指导原则的关键考虑因素:寡核苷酸基治疗药物的非临床安全性评价

2026-01-011
PRE
Apoptotic signatures allow early and rapid screening of drug-induced liver injury to accelerate drug discovery

凋亡标志物能够实现药物诱导性肝损伤的早期和快速筛查,以加速药物发现。

2025-12-240
OAAI
Opportunities for More Tailored Approaches to Genotoxicity Testing and Carcinogenicity Strategy for Oligonucleotide Therapeutics: Outcome of an Industry Survey
2025-02-010
PRE
Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry Recommendations

评估治疗性寡核苷酸的杂交依赖性脱靶风险: 最新行业建议

2025-02-010
PRE
Glucagon Like Peptide 1 Receptor Agonists for Targeted Delivery of Antisense Oligonucleotides to Pancreatic Beta Cell
2021-02-2440
PREAI
The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages
2016-05-06134
OAAI